Dan Janney is the Managing Partner of Alta Partners, a San Francisco-based venture capital firm. See sector focus and contact routes.
Dan Janney is the Managing Partner of Alta Partners, a San Francisco-based venture capital firm, where he has served since the firm’s founding in 1996 and brings over 25 years of early-stage life sciences investing experience. His investment thesis centers on early-stage companies leveraging novel biological insights and new drug discovery approaches, primarily within the life sciences and biotechnology sectors. Janney typically leads investments with check sizes ranging from $100,000 to $5.0 million, with a sweet spot around $1.5 million, and is known for taking lead roles rather than following. Notable portfolio companies he has led include Krystal Biotech (NASDAQ: KRYS), Allakos (NASDAQ: ALLK), Dynavax (NASDAQ: DVAX), and InterMune (NASDAQ: ITMN), many of which later went public or were acquired. He currently serves on the boards of Be Biopharma, Krystal Biotech, Lassen Therapeutics, and Progentos Therapeutics, reflecting his active governance role. While Janney has not published public writing, his distinctive point of view emphasizes partnering with entrepreneurs to build companies around transformative biology rather than incremental improvements
Every field above is read from the StartupFundraising investor directory — disclosed location, recorded investments and stated focus — and re-checked as filings arrive. Founders pair it with investors in San Francisco when building a target list.
Investors like Dan Janney · Full investor directory · Investor access · Company funding database